MediPharm Labs Inc.. Signs Cannabis Concentrate Program Agreement With James E. Wagner Cultivation Corporation

MediPharm Labs Inc..

Signs Cannabis Concentrate Program Agreement With James E. Wagner Cultivation Corporation

James E. Wagner Cultivation Corporation (TSX VENTURE:JWCA) is very happy to announce that it has entered into a Cannabis Concentrate Program Agreement dated July 31, 2018 with MediPharm Labs Inc. (“MediPharm“) farther to the Company’s press release dated June 18, 2018. Pursuant to the Agreement, the parties have entered into a commercial arrangement whereby JWC will provide MediPharm with dried cannabis to use for the purposes of producing cannabis oil.

Subject to the bulk transfer approval of Health Canada, JWC will send dried cannabis to MediPharm that MediPharm will use to produce cannabis oil. The parties intend that under the Program, MediPharm may provide cannabis oil to JWC or to other licensed producers of medical cannabis at the management of JWC. Alternatively, JWC may release the cannabis extract for use by MediPharm. The Program will be established at no capital cost to JWC; however, MediPharm will charge JWC processing charges for the cannabis oil produced, and the revenue earned on sales of cannabis oil by MediPharm will be shared between MediPharm and JWC.

Nathan Woodworth, JWC’s President and Chief Executive Officer, said:”Oil is an important product form from the cannabis industry, and JWC is pleased to be working with a business that offers a special path to providing high quality oils to our patients. ”

Pat McCutcheon, MediPharm’s President and Chief Executive Officer, said: “We’re very excited to deliver an oil strategy to these innovative leaders in the cannabis area. ”

The Program will be for an initial term of 3 decades.

About MediPharm Labs Inc..

Founded in 2015, MediPharm is a pioneer in the cannabis industry and has the distinction of being the first company in Canada to become a certified manufacturer for cannabis oil production below the accessibility to Cannabis for Medical Purposes Regulations (ACMPR) without first receiving a cannabis cultivation licence. This specialist focus on cannabis targets from our cGMP (current Good Manufacturing Practices) and ISO standard clean rooms and critical environments laboratory, allows MediPharm to work with its established, Health Canada-approved cultivation partners to produce pharmaceutical-grade cannabis oil with a competitive advantage. MediPharm is research-driven and focused on downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification. MediPharm supplies B2B contract processing of cannabis to Canadian authorized licensed producers and appropriate foreign growers, providing integrity-assured cannabis oil to qualified companies for sale under their own brand. Additionally, MediPharm will supply raw materials, formulations, processing and packaging to the creation of ready-to-sell advanced derivative products. Through its subsidiary, MediPharm Labs Australia Pty. Ltd., MediPharm has also finished its application process with the federal Office of Drug Control to extract and import medical cannabis products in Australia.

For additional information about MediPharm, please see the company’s website: www.medipharmlabs.com.

JWC’s wholly-owned subsidiary is a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations and JWC is a superior cannabis brand, focusing on creating clean, consistent cannabis. JWC uses an advanced and proprietary aeroponic platform named GrowthStorm&commerce;. JWC began as a collective of patients and growers under the Marijuana Medical Access Regulations (the precursor to ACMPR). JWC’s operations are based in Kitchener, Ontario.

For additional Information Regarding JWC, please consult with JWC’s profile on SEDAR (www.sedar.com) or the Organization ’s website: https://www.jwcmed.com/home.html

This press release contains forward-looking statements about JWC and its business that might include, but is not limited to, risk, uncertainties and other factors that may cause actual events to differ materially from current expectations. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or whatsoever and could differ materially as a result of known and unknown risk factors and uncertainties affecting JWC. By way of example, there can be no guarantee that the Program will proceed as intended by the parties and set out in the Agreement. Other risk factors include risks about the cannabis industry, economic factors, the equity markets generally and risks associated with growth and competition. Although JWC has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there can be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Readers are cautioned not to put undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information about this release, please contact Nathan Woodworth, the President and Chief Executive Officer of JWC:

Email: nathan@jwcmed.com
Telephone: -LRB-519-RRB- 594-0144 x421

Source: GlobeNewswire (July 31, 2018 – 5:00 PM EDT)

Released at Tue, 31 Jul 2018 21:41:26 +0000

Posted in: News

Comments are closed.